Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
But GHK-Cu is not an uncomplicated ingredient to work with
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Neuropharmacology, 171, 108104
Anti-inflammatory action: It reduces pro-inflammatory cytokines without the side effects associated with NSAIDs
Does peptide therapy replace standard PMOS treatment
US$ 21.09
US$ 29.43
US$ 20.64
US$ 27.28
US$ 20.73
US$ 21.57
US$ 23.85
US$ 25.01
US$ 22.59
US$ 22.42
US$ 26.96
US$ 21.34
